Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosnilimab - AnaptysBio

Next Previous
Drug Profile

Rosnilimab - AnaptysBio

Alternative Names: ANB-030

Latest Information Update: 18 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AnaptysBio
  • Class Anti-inflammatories; Antibodies; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Programmed cell death 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alopecia areata; Rheumatoid arthritis; Ulcerative colitis
  • Phase I Autoimmune disorders

Most Recent Events

  • 06 Aug 2025 AnaptysBio completes enrolment in the phase II ROSETTA trial in Ulcerative colitis in USA, Austria, Bulgaria, Canada, Croatia, France, Germany, Italy, Netherlands, Poland, Romania, Spain, Georgia, Serbia and the United Kingdom (SC) (NCT06127043)
  • 03 Jun 2025 Efficacy and adverse events data from a phase-IIb RENOIR trial in Rheumatoid arthritis released by AnaptysBio
  • 27 Feb 2025 Efficacy and adverse events data from the phase IIb RENOIR trial in Rheumatoid arthritis released by AnaptysBio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top